Frozen Does Not Mean Stable: Rethinking Cryopreservation in Cell and Gene Therapy Manufacturing
As cell-based therapies grow more complex and manufacturing networks expand, resilience can’t be an afterthought,…
Frozen Does Not Mean Stable: Rethinking Cryopreservation in Cell and Gene Therapy Manufacturing
As cell-based therapies grow more complex and manufacturing networks expand, resilience can’t be an afterthought, and cryopreservation can no longer just be a step that gets validated during development and left alone. It needs to play an ongoing role in product consistency, potency, and reliability. The post Frozen Does Not Mean Stable: Rethinking Cryopreservation in…
DPC Is Scaling — The Financing Architecture Isn’t Ready
Growth without structural discipline creates risk. And the risk that has gone largely unexamined in the DPC advocacy space is the one that matters most to the broader healthcare system: what happens to insurance risk pools when healthy lives migrate out of them? The post DPC Is Scaling — The Financing Architecture Isn’t Ready appeared…
Personalized Rehab Solution: Supporting Patients With Work Responsibilities
[Sponsored] Balancing recovery with professional obligations can feel overwhelming. The post Personalized Rehab Solution: Supporting Patients With Work Responsibilities appeared first on MedCity News.
New KFF Tracking Poll on Health Information and Trust Finds One in Three Adults Have Used AI Chatbots for Health Advice — The Monitor
KFF’s latest Tracking Poll finds that one-third of the public report using AI chatbots for health information and advice in the past year. And a federal judge suspended, for now, the appointments of thirteen members of ACIP, halting a scheduled meeting and staying recent, widely debated, changes to the childhood vaccine schedule.
Taking a GLP-1? Doctors Say Not To Forget About Movement and Mental Health
LISTEN: Taking a GLP-1? Doctors say don’t forget to move your body and tend to your mental health, too. Severe ankle pain drove Jelon Smart to start taking a weight loss injection a year and a half ago. Smart was 285 pounds and worked as a caterer in Savannah, Georgia. After she’d been standing on…
With AI, why do we still have radiologists?
From Lex Fridman’s interview with Jensen Huang, CEO of NVIDIA: …the first job that computer scientists said, AI researchers said was gonna go away was radiology because computer vision was going to achieve superhuman levels…and it did. Computer vision was superhuman in 2019….maybe a little bit later, 2020. And so it’s been a long time…
Could There Be a ‘Soft Opening’ of H.R. 1 Medicaid Changes?
Experts are split on whether H.R. 1 Medicaid changes in 2027 will roll out gradually or on schedule. The post Could There Be a ‘Soft Opening’ of H.R. 1 Medicaid Changes? appeared first on MedCity News.
Adonis Scores $40M for AI Platform Aiming to Boost Hospital Revenue
Adonis raised a $40 million Series C funding round to help hospitals use AI to tackle denied and underpaid claims. Its platform automates manual revenue cycle tasks and provides real-time insights, which allows staff to focus on higher-value work. Customers include Mount Sinai Health System, Baptist Health South Florida, AdventHealth and ApolloMD. The post Adonis…
CDC’s Acting Chief Promises a Return to Stability in a Tumultuous Moment
President Donald Trump will soon nominate a permanent director for the Centers for Disease Control and Prevention, its acting chief, National Institutes of Health Director Jay Bhattacharya, told agency employees at a Wednesday staff meeting. According to a recording obtained by KFF Health News, Bhattacharya at one point suggested to CDC staff that Trump could…
Merck’s $6.7B Terns Acquisition Positions It to Challenge a Blockbuster Novartis Cancer Drug
Merck has been acquiring assets that could help make up for the coming revenue decline as its top product, the cancer drug Keytruda, drops off the patent cliff. Terns Pharmaceuticals’ lead product candidate, in development for treating a type of leukemia, could offer dosing and efficacy advantages over the Novartis drug Scemblix. The post Merck’s…
